Hims & Hers Health, Inc. (HIMS)
| Market Cap | 6.40B -42.9% |
| Revenue (ttm) | 2.58B +28.0% |
| Net Income | -142.03M |
| EPS | -0.62 |
| Shares Out | 233.31M |
| PE Ratio | n/a |
| Forward PE | 77.25 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,553,511 |
| Open | 27.30 |
| Previous Close | 27.90 |
| Day's Range | 27.12 - 28.00 |
| 52-Week Range | 13.74 - 65.30 |
| Beta | 2.41 |
| Analysts | Hold |
| Price Target | 31.23 (+13.81%) |
| Earnings Date | Aug 10, 2026 |
About HIMS
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, Australia, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter ... [Read more]
Financial Performance
In 2025, Hims & Hers Health's revenue was $2.35 billion, an increase of 59.00% compared to the previous year's $1.48 billion. Earnings were $128.37 million, an increase of 1.85%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $31.23, which is an increase of 13.81% from the latest price.
News
Kaplan Fox Advises Hims & Hers Health, Inc. (HIMS) Investors to Act Before the Lead Plaintiff Deadline on November 2, 2026
New York, New York--(Newsfile Corp. - September 10, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Com...
Kaplan Fox Urges Investors of Hims & Hers Health, Inc. (NYSE: HIMS) with Significant Losses to Seek a Leadership Role Before November 2, 2026
NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: H...
Kaplan Fox Reminds Hims & Hers Health, Inc. (HIMS) Investors with Significant Losses to Seek a Leadership Role Before Deadline on November 2, 2026
New York, New York--(Newsfile Corp. - September 4, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Comp...
HIMS & HERS HEALTH, INC. (HIMS) INVESTOR ALERT Investors With Large Losses in Hims & Hers Health, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acqui...
Hims & Hers Health Bolsters International Footprint with Australian Launch
Telehealth platform Hims & Hers Health ($HIMS) is strengthening its international presence by expanding into Australia. This marks the company’s foray into the Asia-Pacific market. The move follows th...
Hims Arrives in Australia, Bringing Personalised Care for Men Nationwide
SYDNEY--(BUSINESS WIRE)--Hims & Hers, the leading global health and wellness platform, today announced it is officially launching the Hims brand in Australia and bringing its personalised care platfor...
Hims Enters Australia, Marking First Expansion into the Asia-Pacific Market
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced it is now serving customers in Australia, marking the company's ...
Hims & Hers offers GLP-1 weight-loss drugs, men's health treatments in Australia
Telehealth company Hims & Hers said on Monday it has begun offering branded GLP-1 weight-loss drugs and other treatments to men in Australia as it continues to expand its international business.
Kaplan Fox Encourages Investors of Hims & Hers Health, Inc. (HIMS) to Contact the Firm to Learn About Their Legal Rights
New York, New York--(Newsfile Corp. - August 31, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") ...
Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (NYSE: HIMS)
PHILADELPHIA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC announces an investigation into the Board of Directors of Hims & Hers Health, Inc. (NYSE: HIMS) (“Hims ...
Kaplan Fox is Investigating Hims & Hers Health, Inc. (HIMS) for Potential Violations of the Federal Securities Laws
New York, New York--(Newsfile Corp. - August 28, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") ...
Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (HIMS)
Philadelphia, Pennsylvania--(Newsfile Corp. - August 26, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into the Board of Directors of Hims & Hers Health, Inc. (NY...
Hims & Hers Health, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, Aug. 25, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Hims & Hers Health, Inc., (“Hims" or the "Company") (NYSE: HIMS) investors that the firm has initiated an investigation into...
Hims & Hers’ weight-loss plans draw penalties by Visa, Bloomberg reports
Hims & Hers (HIMS) has been placed in Visa’s (V) Acquirer Monitoring Program after a surge in weight-loss subscription disputes, adding scrutiny to its billing practices and creating potential operati...
Hims & Hers Health Hit With Visa Penalties as Weight-Loss Complaints Surge
Telehealth company Hims & Hers Health ($HIMS) is facing penalties from payments giant Visa ($V) after customer credit card disputes in its weight-loss subscription business surged beyond acceptable li...
Watch CNBC's full interview with Hims & Hers CEO Andrew Dudum
In an exclusive interview, Hims & Hers CEO Andrew Dudum sits down with Squawk Box Co-Anchor Andrew Ross Sorkin and shares his perspective on how AI can transform healthcare, the company's transition f...
Hims & Hers CEO says FTC lawsuit misunderstands how the company works
Hims & Hers CEO Andrew Dudum defended the company against against an FTC lawsuit over its data sharing and subscription practices. In an interview with CNBC, he also said the company's sale of compoun...
As Hims prepares for peptides launch, Wall Street cautious on prospects this year
Hims & Hers Health plans to offer some legally available peptides in 2026, but investors and analysts who spoke to Reuters after the telehealth company's quarterly results this week said sales for th...
Hims & Hers Stock (HIMS) Slides as GLP-1 Push Swallows Profits and Widens Q2 Loss
Shares of Hims & Hers Health ($HIMS), a U.S. telehealth firm, fell over 7% in premarket trading on Tuesday after reporting a more-than-expected Q2 loss. The decline reversed slightly after…
Tuesday's Morning Movers: RKLB & HIMS Earnings, RIOT Gets Anthropic Deal
Hims & Hers (HIMS) shares struggled to find their footing after the company posted a quarterly loss despite seeing revenue and guidance rise. Sam Vadas discusses the earnings and the price action foll...
HIMS Stock Sinks on Earnings Miss and Margin Pressure; Analysts Divided
Shares of Hims & Hers ($HIMS) were down 6.3% in premarket trading after the telehealth company reported mixed second-quarter results. A wider-than-expected loss and weaker margins overshadowed strong ...
Hims & Hers shares slide as costly weight-loss push squeezes margins
Hims & Hers Health's shares fell nearly 7% in premarket trading on Tuesday, as concerns over shrinking profit margins overshadowed strong subscriber growth and a raised annual revenue forecast.
AST SpaceMobile, Intel, On, Hims, and More Stocks That Explain Today's Market
Stocks looked set to struggle for direction on Tuesday as investors worried about inflation, with hopes of Iran agreeing a deal to reopen the crucial Strait of Hormuz shipping route fading fast.
Hims & Hers stock drops 7% despite higher guidance: what went wrong?
Shares of Hims & Hers Health fell more than 7% in premarket trading on Tuesday after the telehealth company reported a wider-than-expected second-quarter loss, as investments in branded GLP-1 weight-l...
Hims & Hers Health Earnings Call Transcript: Q2 2026
Q2 2026 saw 40% revenue growth to $753M and nearly 3M subscribers, driven by AI-powered care, international expansion, and strong weight loss and hormonal health demand. Adjusted EBITDA margin improved to 8%, with guidance raised for 2026 and robust investments in technology and global scale.